secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001193125-25-272363
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q3 net loss $71.6M, appoints new CFO
---------------------------------------------

- Net loss $71.6M ($8.36/diluted share) vs $1.4M ($0.44) YoY; driven by $40.7M non-cash tranche liability loss and $20.9M other expense.
- Revenue fell to $1.0M (all from related party) from $10.0M in Q3 2024, due to absence of Boehringer Ingelheim milestone payment.
- Cash $81.3M at Sep 30, 2025 (down from $90.4M at Jun 30); R&D $7.8M vs $5.2M, G&A $4.1M vs $3.6M YoY.
- Andrew Maleki appointed CFO effective Nov 12, 2025; Charles Williams continues as COO and Secretary.
- Company on track to submit IND for SZN-8141 in 2026; ophthalmology pipeline remains focus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000119312525272363/0001193125-25-272363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000119312525272363/srzn-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-272363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer